190 related articles for article (PubMed ID: 38287168)
21. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
[TBL] [Abstract][Full Text] [Related]
23. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma.
Wen C; Deng X; Ren D; Song X; Chen H; Wang J; Jin J; Cheng D; Xu Z; Zhang J; Xie J; Qi W; Gu J; Peng C; Chen D; Chen S; Shen B; Zhan Q
Cancer Med; 2020 Oct; 9(20):7626-7636. PubMed ID: 32862515
[TBL] [Abstract][Full Text] [Related]
24. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
[TBL] [Abstract][Full Text] [Related]
25. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
[TBL] [Abstract][Full Text] [Related]
26. Prognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based on Proteomics.
Kou YQ; Yang YP; Pan ZJ; Du SS; Yuan WN; He K; Nie B
Med Sci Monit; 2023 Mar; 29():e938785. PubMed ID: 36905103
[TBL] [Abstract][Full Text] [Related]
27. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
28. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients.
Tian M; Cui YZ; Song GH; Zong MJ; Zhou XY; Chen Y; Han JX
BMC Cancer; 2008 Aug; 8():241. PubMed ID: 18706098
[TBL] [Abstract][Full Text] [Related]
30. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
31. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
32. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
O'Rourke MB; Sahni S; Samra J; Mittal A; Molloy MP
J Proteomics; 2021 Jan; 231():103998. PubMed ID: 33027703
[TBL] [Abstract][Full Text] [Related]
33. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.
Li Q; Wang H; Zogopoulos G; Shao Q; Dong K; Lv F; Nwilati K; Gui XY; Cuggia A; Liu JL; Gao ZH
Oncotarget; 2016 Nov; 7(47):77838-77853. PubMed ID: 27788482
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
Front Immunol; 2021; 12():790661. PubMed ID: 34925373
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy.
Sahni S; Nahm C; Ahadi MS; Sioson L; Byeon S; Chou A; Maloney S; Moon E; Pavlakis N; Gill AJ; Samra J; Mittal A
Cancer Med; 2023 Sep; 12(17):18050-18061. PubMed ID: 37533202
[TBL] [Abstract][Full Text] [Related]
36. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2016 Aug; 39(4):379-88. PubMed ID: 27240826
[TBL] [Abstract][Full Text] [Related]
37. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
38. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma.
Kitamura F; Miyata T; Uemura N; Uchihara T; Imai K; Hayashi H; Yamashita YI; Matsusaki K; Ishimoto T; Baba H
Anticancer Res; 2021 Jun; 41(6):2895-2900. PubMed ID: 34083280
[TBL] [Abstract][Full Text] [Related]
39. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance.
Ma MZ; Kong X; Weng MZ; Cheng K; Gong W; Quan ZW; Peng CH
J Exp Clin Cancer Res; 2013 Sep; 32(1):71. PubMed ID: 24289824
[TBL] [Abstract][Full Text] [Related]
40. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Nicolle R; Gayet O; Duconseil P; Vanbrugghe C; Roques J; Bigonnet M; Blum Y; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Puleo F; Augustin J; Emile JF; Svrcek M; Arsenijevic T; Hammel P; Giovannini M; Grandval P; Dahan L; Moutardier V; Gilabert M; Van Laethem JL; Bachet JB; Cros J; Iovanna J; Dusetti NJ
Ann Oncol; 2021 Feb; 32(2):250-260. PubMed ID: 33188873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
